keyword
MENU ▼
Read by QxMD icon Read
search

Ovarian cancer biomarker

keyword
https://www.readbyqxmd.com/read/29036807/obtaining-and-characterization-of-monoclonal-antibodies-against-recombinant-extracellular-domain-of-human-epidermal-growth-factor-receptor-2
#1
Sarina Nurgul, Abeldenov Sailau, Turgimbayeva Aigerim, Zhylkibayev Assylbek, Ramankulov Erlan, Khassenov Bekbolat, Eskendirova Saule
Human epidermal growth factor receptor 2 (HER2) is an important biomarker for detection and treatment of different types of cancers such as breast, ovarian, stomach cancer. In this study, we developed a monoclonal antibody against the extracellular domain (ECD) of HER2 biomarker of breast cancer. For this purpose, the ECD-HER2 gene was amplified and cloned into an expression vector. Gene was generated in Escherichia coli BL21 (DE3) strain for expression of recombinant protein. The expressed protein was separated by SDS-PAGE and detected by anti-his monoclonal antibody in immunoblotting...
September 8, 2017: Human Antibodies
https://www.readbyqxmd.com/read/29036787/evaluation-of-serum-ccl18-as-a-potential-biomarker-for-ovarian-cancer
#2
Linjing Yuan, Jianxin Wan, Chumei Huang, Jingjing Liang, Min Liu, Caifeng Yue, Laisheng Li
BACKGROUND: Early detection and differentiation diagnosis of a pelvic mass (PM) is crucial in improving the prognosis of patients with epithelial ovarian cancer (EOC). C-C motif chemokine ligand 18 (CCL18) was reported as a chemokine-mediated tumor-related inflammation that can be detected in serum and may correlate with cancer patients' prognosis. OBJECTIVE: We performed this study to investigate the relationship between CCL18 levels and clinical characteristics of EOC patients, and to explore their diagnostic and prognostic values...
September 29, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29034816/clinical-performance-of-loci%C3%A2-based-tumor-marker-assays-for-tumor-markers-ca-15-3-ca-125-cea-ca-19-9-and-afp-in-gynecological-cancers
#3
Ramona C Dolscheid-Pommerich, Mignon Keyver-Paik, Thomas Hecking, Walther Kuhn, Gunther Hartmann, Birgit Stoffel-Wagner, Stefan Holdenrieder
Evidence is sparse regarding the clinical performance of luminescent oxygen channeling immunoassays-based tumor marker assays in gynecological cancer. Analyzing serum samples of 336 patients with Dimension™Vista1500, we investigated the diagnostic power of carbohydrate antigen 15-3, carbohydrate antigen 125, carcinoembryonic antigen, carbohydrate antigen 19-9, and alpha-fetoprotein in patients suffering from different types of gynecological cancer and precancerous gynecological diseases and compared findings to appropriate control groups...
October 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29020678/ovarian-cancer-a-heterogeneous-disease
#4
Myriam Kossaï, Alexandra Leary, Jean-Yves Scoazec, Catherine Genestie
Ovarian cancer encompasses a collection of neoplasms with distinct clinicopathological and molecular features and prognosis. Despite there being a variety of ovarian cancer subtypes, these are treated as a single disease. Tremendous efforts have been made to characterize these subtypes and identify tumoral pathways and potential biomarkers for therapeutic strategies. As in other cancer types, tumor heterogeneity appears to be very high across subtypes and within a single tumor, representing a major cause of treatment failure...
October 12, 2017: Pathobiology: Journal of Immunopathology, Molecular and Cellular Biology
https://www.readbyqxmd.com/read/29019869/the-analysis-of-cell-cycle-related-proteins-in-ovarian-clear-cell-carcinoma-versus-high-grade-serous-carcinoma
#5
Yukiko Hazama, Takuya Moriya, Mika Sugihara, Rikiya Sano, Mitsuru Shiota, Takafumi Nakamura, Koichiro Shimoya
In Japan, the frequency of ovarian clear cell carcinoma (CCC) is twice as high as that in the United States and Europe. Often, patient prognosis of CCC is poor because of chemoresistance. Here, we focus on the cell cycle, which is one of the mechanisms of chemoresistance. To detect the informative markers and improve the strategy of chemotherapy for CCC, we performed immunochemical staining of cell cycle-related proteins in ovarian malignant tumors. We detected that each of the 29 samples of CCC and high-grade serous carcinoma (HGSC) were necessary to reveal the significant differences in immunostaining and prognosis...
October 10, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/29017919/whole-cell-biopanning-with-a-synthetic-phage-display-library-of-nanobodies-enabled-the-recovery-of-follicle-stimulating-hormone-receptor-inhibitors
#6
Ronan Crepin, Gianluca Veggiani, Selma Djender, Anne Beugnet, François Planeix, Christophe Pichon, Sandrine Moutel, Sebastian Amigorena, Franck Perez, Nicolae Ghinea, Ario de Marco
Antibodies are essential reagents that are increasingly used in diagnostics and therapy. Their specificity and capacity to recognize their native antigen are critical characteristics for their in vivo application. Follicle-stimulating hormone receptor is a GPCR protein regulating ovarian follicular maturation and spermatogenesis. Recently, its potentiality as a cancer biomarker has been demonstrated but no antibody suitable for in vivo tumor targeting and treatment has been characterized so far. In this paper we describe the first successful attempt to recover recombinant antibodies against the FSHR and that: i) are directly panned from a pre-immune library using whole cells expressing the target receptor at their surface; ii) show inhibitory activity towards the FSH-induced cAMP accumulation; iii) do not share the same epitope with the natural binder FSH; iv) can be produced inexpensively as mono- or bivalent functional molecules in the bacterial cytoplasm...
October 7, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28984489/directing-the-use-of-ddr-kinase-inhibitors-in-cancer-treatment
#7
Inger Brandsma, Emmy D G Fleuren, Chris T Williamson, Christopher J Lord
Introduction Defects in the DNA damage response (DDR) drive the development of cancer by fostering DNA mutation but also provide cancer-specific vulnerabilities that can be exploited therapeutically. The recent approval of three different PARP inhibitors for the treatment of ovarian cancer provides the impetus for further developing targeted inhibitors of many of the kinases involved in the DDR, including inhibitors of ATR, ATM, CHEK1, CHEK2, DNAPK and WEE1. Areas covered We summarise the current stage of development of these novel DDR kinase inhibitors, and describe which predictive biomarkers might be exploited to direct their clinical use...
October 6, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28984201/identification-of-common-oncogenic-and-early-developmental-pathways-in-the-ovarian-carcinomas-controlling-by-distinct-prognostically-significant-microrna-subsets
#8
Vladimir A Kuznetsov, Zhiqun Tang, Anna V Ivshina
BACKGROUND: High-grade serous ovarian carcinoma (HG-SOC) is the dominant tumor histologic type in epithelial ovarian cancers, exhibiting highly aberrant microRNA expression profiles and diverse pathways that collectively determine the disease aggressiveness and clinical outcomes. However, the functional relationships between microRNAs, the common pathways controlled by the microRNAs and their prognostic and therapeutic significance remain poorly understood. METHODS: We investigated the gene expression patterns of microRNAs in the tumors of 582 HG-SOC patients to identify prognosis signatures and pathways controlled by tumor miRNAs...
October 3, 2017: BMC Genomics
https://www.readbyqxmd.com/read/28978006/mitochondrial-mrna-transcripts-predict-overall-survival-tumor-recurrence-and-progression-in-serous-ovarian-cancer-companion-diagnostics-for-cancer-therapy
#9
Federica Sotgia, Michael P Lisanti
Here, we performed a systematic analysis to discover new biomarkers of overall survival and tumor progression in ovarian cancer patients. More specifically, we determined whether nuclear-encoded mitochondrial genes related to mitochondrial biogenesis and function are effective in predicting clinical outcome in ovarian cancer. As a consequence, we are able to provide in silico validation of the prognostic value of these mitochondrial markers, in a well-defined population of ovarian cancer patients. Towards this end, we used a group of N=111 ovarian cancer patients (serous type; stage III), with optimal de-bulking...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28977941/ccne1-expression-in-high-grade-serous-carcinoma-does-not-correlate-with-chemoresistance
#10
Stav Sapoznik, Sarit Aviel-Ronen, Keren Bahar-Shany, Oranit Zadok, Keren Levanon
Delayed diagnosis of ovarian cancer, as well as high recurrence rates and lack of personalized therapy options, are among the causes for poor survival figures. Much effort is made towards developing new therapeutic possibilities, however predictive biomarkers are still unavailable. CCNE1 amplification, occurring in ∼20% of the high grade serous ovarian tumors, was previously proposed as a marker for platinum resistance and poor prognosis as well as for CDK2 inhibition. The current study aimed to examine the role of CCNE1 positive-immunostain as a predictor of first-line taxane-platinum chemoresistance...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28976449/a-2-protein-signature-predicting-clinical-outcome-in-high-grade-serous-ovarian-cancer
#11
Chengjuan Jin, Yingfeng Xue, Yingwei Li, Hualei Bu, Hongfeng Yu, Tao Zhang, Zhiwei Zhang, Shi Yan, Nan Lu, Beihua Kong
OBJECTIVE: High-grade serous ovarian cancer (HGSOC) accounts for approximately 70% deaths in ovarian cancer. The overall survival (OS) of HGSOC is poor and still remains a clinical challenge. High-grade serous ovarian cancer can be divided into 4 molecular subtypes. The prognosis of different molecular subtypes is still unclear. We aimed to investigate the prognostic values of immunohistochemistry-based different molecular subtypes in patients with HGSOC. METHODS: We analyzed the protein expression of representative biomarkers (CXCL11, HMGA2, and MUC16) of 3 different molecular subtypes in 110 formalin-fixed, paraffin-embedded HGSOC by tissue microarrays...
October 3, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28970963/ultrasensitive-tumour-penetrating-nanosensors-of-protease-activity
#12
Ester J Kwon, Jaideep S Dudani, Sangeeta N Bhatia
The ability to identify cancer lesions with endogenous biomarkers is currently limited to tumours ~1 cm in diameter. We recently reported an exogenously administered tumour-penetrating nanosensor that sheds, in response to tumour-specific proteases, peptide fragments that can then be detected in the urine. Here, we report the optimization, informed by a pharmacokinetic mathematical model, of the surface presentation of the peptide substrates to both enhance on-target protease cleavage and minimize off-target cleavage, and of the functionalization of the nanosensors with tumour-penetrating ligands that engage active trafficking pathways to increase activation in the tumour microenvironment...
2017: Nature biomedical engineering
https://www.readbyqxmd.com/read/28969705/report-on-the-first-slfn11-monothematic-workshop-from-function-to-role-as-a-biomarker-in-cancer
#13
Alberto Ballestrero, Davide Bedognetti, Domenico Ferraioli, Paola Franceschelli, Sana Intidhar Labidi-Galy, Elisabetta Leo, Junko Murai, Yves Pommier, Petros Tsantoulis, Valerio Gaetano Vellone, Gabriele Zoppoli
SLFN11 is a recently discovered protein with a putative DNA/RNA helicase function. First identified in association with the maturation of thymocytes, SLFN11 was later causally associated, by two independent groups, with the resistance to DNA damaging agents such as topoisomerase I and II inhibitors, platinum compounds, and other alkylators, making it an attractive molecule for biomarker development. Later, SLFN11 was linked to antiviral response in human cells and interferon production, establishing a potential bond between immunity and chemotherapy...
October 2, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28969424/development-of-a-long-lived-luminescence-probe-for-visualizing-%C3%AE-galactosidase-in-ovarian-carcinoma-cells
#14
Wanhe Wang, Kasipandi Vellaisamy, Guodong Li, Chun Wu, Chung-Nga Ko, Chung-Hang Leung, Dik-Lung Ma
β-Galactosidase (β-gal) is an important biomarker for ovarian cancers. In this work, we designed and synthesized a novel iridium(III)-based probe 1 for discriminating ovarian carcinoma cell lines from normal cell lines. The probe could detect β-gal even in the presence of a highly autofluorescent background. The probe also showed a good linear response to β-gal between 0 and 30 U/mL, with a detection limit of 0.51 U/mL. Importantly, complex 1 could selectively "light up" ovarian carcinoma cells, while exhibiting negligible luminescence in normal cells...
October 3, 2017: Analytical Chemistry
https://www.readbyqxmd.com/read/28969062/identification-of-long-non-coding-rna-signature-for-paclitaxel-resistant-patients-with-advanced-ovarian-cancer
#15
Luqing Wang, Yanjun Hu, Xiaohong Xiang, Kai Qu, Yue Teng
Ovarian cancer is the most lethal gynecologic malignancy, characterized by late diagnosis, frequent relapse, and easy development of chemoresistance. Recent studies suggest that lncRNAs are involved in ovarian cancer onset and progression, as well as the resistance in paclitaxel-containing chemotherapy. However, the genome-wide expression pattern and associated functional implications of lncRNAs in paclitaxel-resistant ovarian cancer cells remain undetermined. In the present study, we identified a panel of lncRNAs aberrantly expressed in both paclitaxel resistant ovarian cancer tissues and cell lines, including XR_948297, XR_947831, XR_938728, XR_938392, NR_103801, NR_073113, and NR_036503...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28966695/ipi59-an-actionable-biomarker-to-improve-treatment-response-in-serous-ovarian-carcinoma-patients
#16
J Choi, S Ye, K H Eng, K Korthauer, W H Bradley, J S Rader, C Kendziorski
Despite improvements in operative management and therapies, overall survival rates in advanced ovarian cancer have remained largely unchanged over the past three decades. Although it is possible to identify high-risk patients following surgery, the knowledge does not provide information about the genomic aberrations conferring risk, or the implications for treatment. To address these challenges, we developed an integrative pathway-index model and applied it to messenger RNA expression from 458 patients with serous ovarian carcinoma from the Cancer Genome Atlas project...
June 2017: Statistics in Biosciences
https://www.readbyqxmd.com/read/28960399/role-of-intracystic-cytokines-and-nitric-oxide-in-ovarian-neoplasms
#17
Agrimaldo Martins Filho, Millena Prata Jammal, Douglas Côbo Micheli, Beatriz Martins Tavares-Murta, Renata Margarida Etchebehere, Eddie Fernando Candido Murta, Rosekeila Simões Nomelini
The development of new biomarkers for the diagnosis and prognosis of ovarian cancer may provide an opportunity for new therapies. In this study, we aimed to compare cytokines (interleukin [IL]-2, IL-5, IL-6, IL-8, IL-10, and tumor necrosis factor [TNF]-α) and nitric oxide (NO) metabolite levels in non-neoplastic tumors, benign primary ovarian tumors, and malignant primary ovarian neoplasms. The secondary aim was to relate cytokine and intracystic NO metabolite levels to clinical, laboratory, and pathologic characteristics for patients with primary ovarian malignancies...
September 28, 2017: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/28950147/genomic-signatures-as-predictive-biomarkers-of-homologous-recombination-deficiency-in-ovarian-cancer
#18
Adriaan Vanderstichele, Pieter Busschaert, Siel Olbrecht, Diether Lambrechts, Ignace Vergote
DNA repair deficiency is a common hallmark of many cancers and is increasingly recognised as a target for cancer therapeutics. Selecting patients for these treatments requires a functional assessment of multiple redundant DNA repair pathways. With the advent of whole-genome sequencing of cancer genomes, it is increasingly recognised that multiple signatures of mutational and chromosomal alterations can be correlated with specific DNA repair defects. The clinical relevance of this approach is underlined by the use of poly-(ADP-ribose) polymerase inhibitors (PARPi) in homologous recombination (HR) deficient high-grade serous ovarian cancers...
September 23, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28944870/effect-of-integrin%C3%A2-linked-kinase-gene-silencing-on-microrna-expression-in-ovarian-cancer
#19
Dandan Yuan, Yilei Zhao, Yang Wang, Jianhua Che, Wenhua Tan, Yuxia Jin, Fei Wang, Peiliang Li, Shuyan Fu, Qian Liu, Wenliang Zhu
Integrin‑linked kinase (ILK) is overexpressed in ovarian cancer (OC), and ILK gene silencing results in apoptosis in OC cells. In the present study, the mechanism by which ILK induces apoptosis was explored from the perspective of microRNA (miRNA) expression. Alterations in the global miRNA expression profile were detected using a miRNA microarray after OC cells were transduced with an ILK small hairpin RNA lentivirus. ILK silencing led to a significant upregulation of 14 miRNAs by at least 1.5‑fold. These findings were validated by reverse transcription‑quantitative polymerase chain reaction...
September 19, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28943904/identification-of-candidate-biomarkers-for-epithelial-ovarian-cancer-metastasis-using-microarray-data
#20
Su Li, Hua Li, Ying Xu, Xiaomei Lv
Epithelial ovarian cancer (EOC) is a common cancer in women worldwide. The present study assessed effective biomarkers for the prognosis of EOC metastasis. The GSE30587 dataset, containing 9 EOC primary tumor samples and 9 matched omental metastasis samples, was analyzed. Following normalization, the differentially expressed genes (DEGs) between these samples were identified using the limma package for R. Subsequently, pathway enrichment analysis was performed using ClueGO, and a protein-protein interaction (PPI) network was constructed using the Search Tool for the Retrieval of Interacting Genes database...
October 2017: Oncology Letters
keyword
keyword
94643
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"